- 专利标题: Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
-
申请号: US17614194申请日: 2020-05-20
-
公开(公告)号: US11672810B2公开(公告)日: 2023-06-13
- 发明人: Michael P. Lisanti , Federica Sotgia
- 申请人: LUNELLA BIOTECH, INC.
- 申请人地址: CA Ottawa
- 专利权人: LUNELLA BIOTECH, INC.
- 当前专利权人: LUNELLA BIOTECH, INC.
- 当前专利权人地址: CA Ontario
- 代理机构: Nixon & Vanderhye, P.C.
- 国际申请: PCT/US2020/033789 2020.05.20
- 国际公布: WO2020/242857A 2020.12.03
- 进入国家日期: 2021-11-24
- 主分类号: A61K31/65
- IPC分类号: A61K31/65 ; A61P35/00 ; A61K31/122 ; A61K31/138 ; A61K31/165 ; A61K31/167 ; A61K31/36 ; A61K31/375 ; A61K31/4375 ; A61K31/44 ; A61K31/47 ; A61K31/4706 ; A61K31/4745 ; A61K31/565 ; A61K31/7004 ; A61K31/7048 ; A61K31/7052 ; G01N33/68
摘要:
MCF7-fibroblast co-cultures are a valuable model of resistance to apoptosis induced by hormonal therapies, such as Tamoxifen and Fulvestrant. These mixed co-cultures demonstrate the induction of mito-sternness and ribo-stemness features. Molecular therapeutic targets were identified through label-free proteomics of MCF7-fibroblast co-cultures, and independently validated using a bioinformatics approach. The resulting Mito-Signature is prognostic of endocrine treatment failure, tumor recurrence, and distant metastasis, and may be used to identify patients at risk of treatment failure. Such patients may be treated with a mitochondrial biogenesis inhibitor to reduce the risk of treatment failure, and/or to increase the effectiveness of the hormone therapy.
公开/授权文献
信息查询